Bold Insight and The Office of Experience partner to deliver outstanding user experiences.
Back to team page
Coleen Long
Director
With a background in clinical, academic, and consumer research, Coleen brings to every project unique, creative insights and an eye for detail. Our clients benefit from her passion for understanding the needs of special populations to develop tools that improve overall quality of life. Coleen has leveraged multiple methods and approaches to lead research across a wide range of industries, including medical technology, commercial products, entertainment, and mental health. Coleen has a BS in Clinical Psychology from the University of Illinois at Urbana-Champaign.
Bold facts
Learn more about
Something unique about you summed up in one sentence:

Your favorite part of working at Bold Insight:

In your spare time (or if you had spare time), you would absolutely do this:
How long have you been in the UX field?

You cannot start the day without doing this...
Your favorite city in the world is...and why?

Your ultimate celebrity dinner party guest list would include:

Do you have a long-term personal or professional goal you'd like to share?
Read our team’s latest bold insights
When designing an experience, are you really thinking about the customer first?
While every organization has constraints to consider when designing experiences for customers or users, designing the ideal customer experience is completely possible within those constraints. Begin by identifying the experience you want your customer to have and work “backward” from there.
UX project logistics: choosing the right vendors for project success
Selecting the correct vendors to support your UX project is critical to success. From facilities to recruiting, knowing the right questions to ask, budget constraints, and client needs and expectations will make the selection process smooth and painless.
Reclassifying diabetes: 3 implications for product design
Recent research suggests that reclassifying diabetes may allow for the development of more targeted diabetes treatments. This could present opportunities to design these treatments to maximize patient safety and experience.